Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 4
2009 10
2010 16
2011 43
2012 82
2013 73
2014 80
2015 85
2016 104
2017 92
2018 107
2019 112
2020 138
2021 103
2022 91
2023 69
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

1,093 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes. ...Adverse events occurred in 34 (64%) participants in the placebo group, 40 (77%) in the …
We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycae …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Rosenstock J, et al. JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269. JAMA. 2019. PMID: 30418475 Free PMC article. Clinical Trial.
Final follow-up occurred on January 18, 2018. INTERVENTIONS: Patients were randomized to receive linagliptin, 5 mg once daily (n = 3494), or placebo once daily (n = 3485) added to usual care. ...MAIN OUTCOMES AND MEASURES: Primary outcome was time to first occurrence of th …
Final follow-up occurred on January 18, 2018. INTERVENTIONS: Patients were randomized to receive linagliptin, 5 mg once daily (n = 34 …
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes.
Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV. Korbut AI, et al. Int J Mol Sci. 2020 Apr 23;21(8):2987. doi: 10.3390/ijms21082987. Int J Mol Sci. 2020. PMID: 32340263 Free PMC article.
We aimed to assess the effect of the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and their combination, on glomerular autophagy in a model of type 2 diabetes. Eight-week-old male db/db mice were randomly assigned to treatment with empagliflozin, linag …
We aimed to assess the effect of the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and their combination, on glomeru …
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES, Deeks ED. Kim ES, et al. Drugs. 2015 Sep;75(13):1547-57. doi: 10.1007/s40265-015-0457-z. Drugs. 2015. PMID: 26323340 Review.
Results of two randomized controlled trials of 52 weeks' duration in adults with T2D demonstrated that empagliflozin/linagliptin improved glycaemic control significantly more than linagliptin when administered as initial therapy (whereas results vs. empagliflozin we …
Results of two randomized controlled trials of 52 weeks' duration in adults with T2D demonstrated that empagliflozin/linagliptin impr …
Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.
Keshavarz K, Lotfi F, Sanati E, Salesi M, Hashemi-Meshkini A, Jafari M, Mojahedian MM, Najafi B, Nikfar S. Keshavarz K, et al. Daru. 2017 Oct 25;25(1):23. doi: 10.1186/s40199-017-0189-6. Daru. 2017. PMID: 29070077 Free PMC article. Review.
Using keywords such as "linagliptin", "type 2 diabetes mellitus", "sitagliptin" and related combinations, we searched databases including Scopus, PubMed, and Web of Science. ...Considering primary and secondary outcomes extracted from the reviewed studies, a network meta-a …
Using keywords such as "linagliptin", "type 2 diabetes mellitus", "sitagliptin" and related combinations, we searched databases inclu …
Linagliptin-induced acute generalized exanthematous pustulosis.
Guanziroli E, Pavia G, Manara SA, Mancini LL, Costanzo A. Guanziroli E, et al. Ital J Dermatol Venerol. 2021 Dec;156(Suppl. 1 to No. 6):99-101. doi: 10.23736/S2784-8671.20.06479-2. Epub 2020 Feb 13. Ital J Dermatol Venerol. 2021. PMID: 32057219 No abstract available.
Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X, Hu J. Tan X, et al. Ann Endocrinol (Paris). 2016 Oct;77(5):557-562. doi: 10.1016/j.ando.2015.11.003. Epub 2016 Apr 6. Ann Endocrinol (Paris). 2016. PMID: 27062036 Review.
Glyxambi() (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) inhibitor with a dipeptidyl peptidase-4 (DPP-4) inhibitor. Glyxambi() is served as an adjuvant to diet and exercise to improve glycemic control in …
Glyxambi() (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) inhibit …
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
Woo V. Woo V. Int J Clin Pract. 2015 Dec;69(12):1427-37. doi: 10.1111/ijcp.12720. Epub 2015 Aug 25. Int J Clin Pract. 2015. PMID: 26303997 Free PMC article. Review.
RESULTS: Empagliflozin/linagliptin STC given as initial therapy or on metformin background lowered mean glycated haemoglobin (HbA1c) by approximately 1.1% (mean baseline HbA1c, 8.0%). ...CONCLUSION: Empagliflozin/linagliptin STC appears to be a rational choice for a …
RESULTS: Empagliflozin/linagliptin STC given as initial therapy or on metformin background lowered mean glycated haemoglobin (HbA1c) …
Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
McKeage K. McKeage K. Drugs. 2014 Oct;74(16):1927-1946. doi: 10.1007/s40265-014-0308-3. Drugs. 2014. PMID: 25297911 Review.
Linagliptin (Trajenta(), Tradjenta()) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. A fixed-dose combination of linagliptin/metformin (Jentadueto()) is also available. This articl …
Linagliptin (Trajenta(), Tradjenta()) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 di …
Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.
Agrawal R, Jain P, Dikshit SN. Agrawal R, et al. Curr Drug Targets. 2012 Jun;13(7):970-83. doi: 10.2174/138945012800675731. Curr Drug Targets. 2012. PMID: 22420306 Review.
Linagliptin was marketed by Lilly under the trade name Tradjenta and Trajenta. Linagliptin was approved as the once-daily dose by USFDA on 2 May 2011, for the treatment of Type-II Diabetes. ...
Linagliptin was marketed by Lilly under the trade name Tradjenta and Trajenta. Linagliptin was approved as the once-daily dose …
1,093 results

Searches related to "linagliptin"